HeartSciences (HSCSW) Common Equity (2021 - 2026)

HeartSciences (HSCSW) has reported Common Equity for 6 consecutive years, with $226060.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 10.18% year-over-year to $226060.0; the trailing twelve-month figure through Apr 2026 stood at $226060.0 (up 10.18% YoY), and the FY2026 full-year result was $226060.0, up 10.18% from the prior year.
• Common Equity climbed to $226060.0 in Q2 2026 per HSCSW's latest filing, from $205171.0 in the prior quarter.
• Across five years, Common Equity topped out at $8.6 million in Q1 2024 and bottomed at -$6.1 million in Q2 2022.
• Historically, Common Equity has averaged $1.5 million across 5 years, with a median of $656616.5 in 2022.
• The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 252.37% in 2023, then surged 3447.59% in 2024.
• Over 5 years, Common Equity stood at $1.1 million in 2022, then sank by 252.37% to -$1.6 million in 2023, then surged by 343.48% to $4.0 million in 2024, then tumbled by 94.89% to $205171.0 in 2025, then grew by 10.18% to $226060.0 in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $226060.0, $205171.0, and $4.2 million for Q2 2026, Q4 2025, and Q4 2025 respectively.